Briquilimab
- Generic Name
- Briquilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2574591-89-0
- Unique Ingredient Identifier
- QWX84D0DRC
- Background
Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06736262
- Locations
- 🇺🇸
Investigative Site 108, Little Rock, Arkansas, United States
🇺🇸Investigative Site 110, Indianapolis, Indiana, United States
🇺🇸Investigative Site 111, Murray, Utah, United States
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma
- Conditions
- Interventions
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06592768
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontatrio, Canada
A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06353971
- Locations
- 🇩🇪
University of Marburg, Marburg, Germany
🇩🇪University of Munster, Munster, Germany
🇩🇪Charité - University Clinic Berlin, Berlin, Germany
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06162728
- Locations
- 🇺🇸
Site 118, Birmingham, Alabama, United States
🇺🇸Little Rock Allergy & Asthma Clinical Research Center, Little Rock, Arkansas, United States
🇺🇸Site 117, Fremont, California, United States
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 90
- Registration Number
- NCT05357482
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.